MedDataX Logo

18F-Fluorodeoxyglucose Positron Emission Tomography in Oncology and Neurology

NCT ID: NCT01180751

Last Updated: 2013-08-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

1000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-07-31

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial is being conducted to study the use of a radioactive glucose tracer as an imaging test \[Positron Emission Tomography (PET)scan\] in adults who have or are suspected of having cancer and in another group of adults to assess for neurologic conditions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tumors

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Positron Emission Tomography Fluorodeoxyglucose FDG (18F-Fluorodeoxyglucose) Oncology Neurology

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

[18F]-Fluorodeoxyglucose

Scanning Procedure: Non-diagnostic Computed Tomography (CT) scan followed by a Diagnostic Positron Emission Tomography (PET) scan.

Group Type OTHER

[18F]-Fluorodeoxyglucose

Intervention Type RADIATION

With each Positron Emission Tomography/Computed Tomography (PET/CT)scan an intravenous administration of radioactive glucose (FDG)is given. This is a weight dependent dosage.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

[18F]-Fluorodeoxyglucose

With each Positron Emission Tomography/Computed Tomography (PET/CT)scan an intravenous administration of radioactive glucose (FDG)is given. This is a weight dependent dosage.

Intervention Type RADIATION

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

FDG (18F-Fluorodeoxyglucose)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Known or suspected primary or metastatic tumours
* A neurological presentation consistent with the list of indications
* 18 years of age or older of either sex
* Able to provide written informed consent
* Able to tolerate the physical and logistical requirements of completing a Positron Emission Tomography (PET)scan
* Karnofsky score \> 60
* Women who are nursing may be included in the study if they are able to discontinue breast feeding for 12 hours

Exclusion Criteria

* Age \<18 years
* Pregnant women; if there is a possibility of pregnancy, bloodwork will be drawn to definitively establish pregnancy status
* Women who are unwilling or unable to discontinue breast feeding for 12 hours post 18F-Fluorodeoxyglucose(FDG) administration
* Subjects who are medically unstable
* Subjects unwilling to provide informed consent.
* Subjects who exceed the safe weight limit of the Positron Emission Tomography (PET) imaging bed or who cannot fit through the PET scanner bore
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Winnipeg Regional Health Authority

OTHER

Sponsor Role collaborator

University of Manitoba

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Winnipeg Regional Health Authority

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Daniel P Levin, BSc,MD,FRCPC

Role: PRINCIPAL_INVESTIGATOR

Winnipeg Regional Health Authority

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Great West Life PET/CT Centre

Winnipeg, Manitoba, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B2010:014

Identifier Type: -

Identifier Source: org_study_id